121 related articles for article (PubMed ID: 12521126)
1. Prognostic value of CA 15.3 kinetics for metastatic breast cancer.
De La Lande B; Hacene K; Floiras JL; Alatrakchi N; Pichon MF
Int J Biol Markers; 2002; 17(4):231-8. PubMed ID: 12521126
[TBL] [Abstract][Full Text] [Related]
2. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis.
Cañizares F; Sola J; Pérez M; Tovar I; De Las Heras M; Salinas J; Peñafiel R; Martínez P
Tumour Biol; 2001; 22(5):273-81. PubMed ID: 11553856
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment values of serum CA 15-3 antigen related to prognostic factors in breast cancer patients.
Wojtacki J; Dziewulska-Bokiniec A; Kowalski DM; Zółtowska A; Ciesielski D; Suszko M
Neoplasma; 1996; 43(4):225-9. PubMed ID: 8931745
[TBL] [Abstract][Full Text] [Related]
4. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
[TBL] [Abstract][Full Text] [Related]
5. Human breast cancer: survival from first metastasis. Breast Cancer Study Group.
Koenders PG; Beex LV; Kloppenborg PW; Smals AG; Benraad TJ
Breast Cancer Res Treat; 1992; 21(3):173-80. PubMed ID: 1515652
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
Molina R; Filella X; Alicarte J; Zanon G; Pahisa J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1035-41. PubMed ID: 12820344
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients.
Vollenweider-Zerargui L; Barrelet L; Wong Y; Lemarchand-Béraud T; Gómez F
Cancer; 1986 Mar; 57(6):1171-80. PubMed ID: 3943040
[TBL] [Abstract][Full Text] [Related]
8. Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.
Bogina G; Lunardi G; Coati F; Zamboni G; Gori S; Bortesi L; Marconi M; Cassandrini PA; Turazza M; Cortesi L; DeMatteis E; Ficarra G; Ibrahim T; Serra P; Medri L; Giraudi S; Lambertini M; Carli F; Foglietta J; Sidoni A; Nunzi M; Ficorella C; Diadema MR; Del Mastro L
Tumori; 2015; 101(4):398-403. PubMed ID: 26045108
[TBL] [Abstract][Full Text] [Related]
9. Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma.
Shering SG; Sherry F; McDermott EW; O'Higgins NJ; Duffy MJ
Cancer; 1998 Dec; 83(12):2521-7. PubMed ID: 9874458
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group.
Bernoux A; de Cremoux P; Lainé-Bidron C; Martin EC; Asselain B; Magdelénat H
Breast Cancer Res Treat; 1998 Jun; 49(3):219-25. PubMed ID: 9776505
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
[TBL] [Abstract][Full Text] [Related]
12. Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse.
Tampellini M; Berruti A; Gorzegno G; Bitossi R; Bottini A; Durando A; De Matteis A; Farris A; Donadio M; De Fabiani E; Manzin E; Arese P; Sarobba MG; Castiglione F; Moro G; Bonazzi G; Nuzzo F; Massobrio M; Dogliotti L
Tumour Biol; 2001; 22(6):367-73. PubMed ID: 11786730
[TBL] [Abstract][Full Text] [Related]
13. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
[TBL] [Abstract][Full Text] [Related]
15. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease.
Tampellini M; Berruti A; Gerbino A; Buniva T; Torta M; Gorzegno G; Faggiuolo R; Cannone R; Farris A; Destefanis M; Moro G; Deltetto F; Dogliotti L
Br J Cancer; 1997; 75(5):698-702. PubMed ID: 9043027
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease.
Berruti A; Tampellini M; Torta M; Buniva T; Gorzegno G; Dogliotti L
Eur J Cancer; 1994; 30A(14):2082-4. PubMed ID: 7857707
[TBL] [Abstract][Full Text] [Related]
17. Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients.
Saghatchian M; Guepratte S; Hacene K; Neumann R; Floiras JL; Pichon MF
Int J Biol Markers; 2004; 19(1):14-22. PubMed ID: 15077922
[TBL] [Abstract][Full Text] [Related]
18. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer.
Kumpulainen EJ; Keskikuru RJ; Johansson RT
Breast Cancer Res Treat; 2002 Nov; 76(2):95-102. PubMed ID: 12452445
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer.
Alexieva-Figusch J; Van Putten WL; Blankenstein MA; Blonk-Van Der Wijst J; Klijn JG
Cancer; 1988 Feb; 61(4):758-68. PubMed ID: 3338038
[TBL] [Abstract][Full Text] [Related]
20. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen.
Bonomi P; Gale M; Von Roenn J; Anderson K; Johnson P; Wolter J; Economou S
Semin Oncol; 1988 Apr; 15(2 Suppl 1):26-33. PubMed ID: 3368797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
